Annual Industry Ranking And Forecast
Exclusive interviews with the CEOs at bluebird bio and Voyager Therapeutics about what could be a standout 2023 for both firms, as well as a look at the life and career of Mads Øvlisen, former CEO of Novo Nordisk and father of CSR.
For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.
Interview: Twelve months on from exiting Biogen, Al Sandrock is once again leading innovation in neuroscience, and hopes to crack the tau nut in Alzheimer’s and prove that Voyager’s next-generation gene therapy system will be a breakthrough.
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.